Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan

First Posted Date: 2008-04-16

Last Posted Date: 2016-08-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21471

Registration Number: NCT00659581

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Enoxaparin
Drug: Dabigatran etexilate

First Posted Date: 2008-04-14

Last Posted Date: 2014-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2055

Registration Number: NCT00657150

Locations: 🇺🇸
1160.64.01003 Boehringer Ingelheim Investigational Site, Missoula, Montana, United States
🇺🇸
1160.64.01002 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇨🇦
1160.64.6011 Boehringer Ingelheim Investigational Site, Oshawa, Ontario, Canada

and more 105 locations

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: placebo
Drug: BIBW 2992

First Posted Date: 2008-04-10

Last Posted Date: 2016-07-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 585

Registration Number: NCT00656136

Locations: 🇧🇪
1200.23.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪
1200.23.32005 Boehringer Ingelheim Investigational Site, Liège, Belgium
🇨🇦
1200.23.1001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

and more 87 locations

Japanese P III vs Voglibose and Placebo

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: voglibose
Drug: BI 1356
Drug: voglibose placebo
Drug: BI 1356 placebo

First Posted Date: 2008-04-08

Last Posted Date: 2014-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 561

Registration Number: NCT00654381

Locations: 🇯🇵
1218.23.33 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵
1218.23.35 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵
1218.23.19 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan

and more 44 locations

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Phase 3

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Pramipexole
Drug: Placebo

First Posted Date: 2008-04-08

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 306

Registration Number: NCT00654498

Locations: 🇨🇳
248.630.06 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳
248.630.07 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳
248.630.01 Boehringer Ingelheim Investigational Site, Shanghai, China

and more 13 locations

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Completed

Conditions: Parkinson Disease

First Posted Date: 2008-04-02

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 286

Registration Number: NCT00651183

Locations: 🇦🇹
Boehringer Ingelheim Investigational Site, Wörgl, Austria

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin + pioglitazone (30 mg)
Drug: placebo + pioglitazone (30 mg)

First Posted Date: 2008-03-21

Last Posted Date: 2014-02-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 389

Registration Number: NCT00641043

Locations: 🇭🇺
1218.15.36002 Boehringer Ingelheim Investigational Site, Szombathely, Hungary
🇪🇸
1218.15.34006 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇬🇷
1218.15.30006 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece

and more 40 locations

Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension

Completed

Conditions: Hypertension

First Posted Date: 2008-03-19

Last Posted Date: 2012-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 33247

Registration Number: NCT00638911

Special Survey Long-term Treatment With Tiotropium on COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2008-03-18

Last Posted Date: 2014-06-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 385

Registration Number: NCT00638183

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Yurihonjo, Japan

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BI 811283 (d 1 and 15)
Drug: BI 811283 (d1)
Drug: Cytarabine

First Posted Date: 2008-03-11

Last Posted Date: 2015-09-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT00632749

Locations: 🇩🇪
1247.3.49004 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪
1247.3.49007 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
1247.3.49005 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy